Listen to the latest news from international experts
Novel imaging biomarkers in MS diagnosis and prognostication
Magnetic resonance imaging (MRI) has emerged as a powerful, noninvasive tool for diagnosis, prognostication, and treatment monitoring in multiple sclerosis (MS). Regional atrophy, T2-weighted lesion accumulation, and T1-weighted gadolinium enhancement are routinely assessed across the disease spectrum. Other imaging biomarkers are under investigation that can detect MS at an earlier stage with greater sensitivity and specificity. Numerous imaging features have been put forward as indicative of MS in the prodromal stages of disease, including the central vein sign and paramagnetic rim lesions. Researchers are also looking to find improved markers of chronic inflammatory activity and disease prognosis. Slowly expanding lesions and brain volumetry are of interest in this space.
In this podcast, experts discuss novel imaging biomarkers in MS and efforts to drive these tools into clinical practice. Jaume Sastre-Garriga, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain; Pascal Sati, PhD, Cedars-Sinai Medical Center, Los Angeles, CA; Letizia Leocani, MD, PhD, Scientific Institute Vita-Salute University San Raffaele, Milan, Italy; and Alberto Calvi, MD, PhD Candidate, UCL Queen Square Institute of Neurology, Barts Health NHS Trust, London, UK, introduce their state-of-the-art research and share insights on what’s to come.
Date: 18th August 2022